

Brand Name: Fasenra

Generic: benralizumab

Type: monoclonal antibody

Year Accepted/Phase: 2017

Mechanism:

Benralizumab binds to the IL-5R α on the surface of eosinophils, leading to their destruction via antibody-dependent cell-mediated cytotoxicity (ADCC) and reducing the number of circulating eosinophils.

Chemical Structure: N/A

Indication:

Fasenra is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.

Clinical trials:

Clinical Trials for Severe Eosinophilic Asthma

Pubmed: <https://pubmed.ncbi.nlm.nih.gov/32882249/>

Purpose: Evaluate the efficacy and safety of benralizumab in patients with severe eosinophilic asthma.

Dates: Clinical trials for Fasenra were conducted in the 2010s.

Results: These trials demonstrated that benralizumab reduced the frequency of asthma exacerbations, improved lung function, and reduced the need for oral corticosteroids in patients with severe eosinophilic asthma.

Impact: The positive results from these trials supported the approval of Fasenra for the treatment of severe eosinophilic asthma.